PPARG and hyperlipidemia: The present study aimed to evaluate the therapeutic potential of the exogenous PPAR-γ ligand rosiglitazone in rats with hyperlipidemic SAP and to examine its effects on hyperlipidemia associated with a critical illness, in order to explore the mechanism of action.